Study indicates the need for a revised definition of functional high risk multiple myeloma.
Researchers have found that with new treatments for multiple myeloma, a serious type of blood cancer, clinicians should use different criteria for identifying patients with poor odds of survival. The study is published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Functional high-risk (FHR) multiple myeloma, which affects a subset of patients with blood cancer, is commonly defined as a multiple myeloma that progresses within 18 months of starting treatment, and it comes with a survival prognosis of less than 2 years after progression. Recently, however, the use of a 4-part treatment regimen—including anti-CD38 antibodies, proteasome inhibitors, immunomodulatory agents, and dexamethasone—followed by autologous stem cell transplantation, has helped to slow the cancer’s progression.
To update the definition of FHR multiple myeloma in the current era of combination therapy, investigators from the University of Alabama at Birmingham and the CoMMiT consortium analyzed information on 310 patients with newly diagnosed multiple myeloma who received this therapy and were followed for a median of 3.5 years.
Survival analyses indicated that cancer progression within 36 months of the onset of combination therapy identified patients whose survival was likely under 2 years from the time of progression. Adding another treatment called T-cell redirecting therapy helped slow progression. This “FHR36” patient population, corresponding to 16.4% of all treated patients, should be prioritized as candidates for early use of T-cell redirecting therapy and for clinical trials of medications with novel mechanisms of action.
“The findings will help physicians choose therapies for this important minority of patients who have disease progression in the first 3 years of diagnosis and identify an important population in greater need for treatment innovations to be addressed in the next generation of clinical trials,” said senior author Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham.
Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com
Full Citation:
“Redefining functional high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT).” Gayathri Ravi, Binod Dhakal, Natalie S Callander, Eva Medvedova, Bhagirathbhai R. Dholaria, Kelly N. Godby, Susan Bal, Forest Huls, Rebecca W Silbermann, and Luciano J. Costa. CANCER; Published Online: July 20, 2026 (DOI: 10.1002/cncr.70478).
URL: http://doi.wiley.com/10.1002/cncr.70478
Author Contact: Adam Pope, public relations manager at the University of Alabama at Birmingham, at arpope@uab.edu or +1 205-934-6986
About the Journal
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on X @JournalCancer, and stay up to date with the American Cancer Society Journals on Instagram, LinkedIn, and YouTube.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.